News | Stents Bioresorbable | July 19, 2016

Good Samaritan Hospital First on West Coast to Offer Absorb Bioresorbable Stent

Retired microbiology professor first California patient to receive fully dissolving, bioresorbable stent following recent FDA approval

Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles

July 19, 2016 — Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with coronary artery disease (CAD) Abbott's Absorb dissolving heart stent. Absorb is a drug-eluting coronary stent that dissolves, completely and naturally, in the body over time.

The stent treats coronary artery disease in a similar fashion to a metallic stent, propping the diseased vessel open to restore blood flow, but then disappears after the artery is healed, leaving no metal behind to restrict natural vessel motion.

Steven Burstein, M.D., interventional cardiologist and medical director of the Cardiac Catherization Laboratory at Good Samaritan Hospital, was the first on the West Coast to implant the Absorb stent to patient Ernest Matson, 69, a retired microbiology professor at the University of Guam, on July 11th. 

According to the National Heart, Lung and Blood Institute, CAD is the most common type of heart disease. CAD is a condition in which the arteries that supply blood to the heart become narrowed or blocked by a buildup of plaque. Plaque is made up of fat, cholesterol, calcium and other deposits that accumulate on the inner wall of the artery. Over time, the plaque hardens and narrows the coronary arteries, limiting the flow of oxygen-rich blood to the heart muscle. Areas of plaque can also rupture, causing a blood clot to form on the surface of the plaque. When blood flow to the heart is reduced or blocked, angina (chest pain) or a heart attack can occur.

While stents are traditionally made of metal, the Absorb stent is made of a naturally dissolving material similar to dissolving sutures. Absorb disappears completely in about three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants.

"With outcomes equivalent to those of the best drug-eluting metallic stents, the Absorb scaffolding will dissolve within 18 to 24 months leaving behind a normal and natural vessel," said Burstein.  "This will not preclude further stenting or bypass surgery and may in fact make these future procedures, if indicated, easier to perform."

For more information: www.abbottvascular.com

Related Content

News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Overlay Init